Imagenetix, Inc. (OTC
Bulletin Board: IAGX), announced today that a new clinical study was
presented at the 4th annual "Natural Supplements: An Evidence-Based Update"
medical conference, hosted by Scripps Center for Integrative Medicine, has
demonstrated that Celadrin(R) can significantly improve knee function and
help relieve the painful symptoms of osteoarthritis. Findings were released
by Imagenetix (imagenetix), an innovator in scientifically tested,
natural-based bioceutical products and maker of Inflame Away(TM)-Celadrin.
The new study -- the fourth clinical study performed on the efficacy of
Celadrin during the past six years -- was conducted and presented by Jay
Udani, M.D., at the Scripps Center for Integrative Medicine conference. Dr.
Udani is a Medical Director of Medicus Research, Medical Director of the
Integrative Medicine Program at Northridge Hospital and Assistant Clinical
Professor at the UCLA/Geffen School of Medicine. The study was awarded
first place in the "Original Clinical Research Category" competition.
The study reported that after eight weeks of taking Inflame
Away-Celadrin capsules, average walking ability increased 45 percent, and
participants claimed a 35 percent decrease in knee discomfort. These
improvements were statistically significantly better than the results seen
in the placebo group, and no negative side effects were found throughout
the entire study.
"This study demonstrates that after two weeks of taking Celadrin
orally, subjects showed significant enhancement of their functional ability
with progressive improvement continuing through the end of the 8 week
study," said Dr. Udani.
The randomized, double-blind, placebo-controlled study, titled "Oral
Cetylated Fatty Acids (Celadrin) for the Improvement of Functional Ability
and Pain in Patients with Moderate Knee Osteoarthritis," evaluated 93
participants over a period of 60 days. Subjects, ranging from 40 to 86
years of age, were evaluated before Celadrin was administered and again
after two, four and eight weeks. During each evaluation, participants were
asked to walk for six minutes to measure how far they could travel with
their knee discomfort.
The participants who consumed Celadrin were able to walk an average
distance of 1183 feet when they started the study. After only two weeks of
taking Celadrin capsules, the average walking distance increased
significantly by about 19 percent, or approximately 232 feet. The
participants continued to improve throughout the study period and after
eight weeks of taking Celadrin capsules; the participants walked an average
distance of 1720 feet -- 45 percent more than when they had started only
two months before.
Non-prescription Inflame Away-Celadrin is available in two forms: a
softgel and a topical cream application.
"Dr. Udani's study further supports the efficacy of Celadrin," said
Robert Hesslink Jr., Sc.D., Director of Research and Development at
Imagenetix. "Our studies conducted in the past have shown that Celadrin can
be used to not only aid in osteoarthritis pain for aging individuals, but
also to alleviate everyday joint discomfort for anyone who is physically
active."
A study on the efficacy of Celadrin-based cream on patients with
osteoarthritis, published in the Journal of Rheumatology in 2004, states
that patients reported a significant relief in joint pain after only 30
minutes of application of the Inflame Away cream formula -- benefits which
continued to improve over time with daily use of the product.
"We are pleased with the results of this award winning study," said
William Spencer, CEO of Imagenetix. "It validates Celadrin's significantly
superior and proven joint health benefits compared to our competitors'
glucosamine, chondroitin, MSM, SAMe, and other natural based joint health
products. Collectively these products represent a market that exceeds $2
billion. Celadrin has once again clinically demonstrated that it works many
times faster and is significantly more effective than
glocosamine/chondroitin combined or any other natural joint health products
on the market today."
About Imagenetix, Inc.
Based in San Diego, Calif., Imagenetix (OTC Bulletin Board: IAGX) is an
innovator of scientifically tested, natural-based, proprietary bioceutical
products developed to enhance human health on a global basis. Imagenetix
develops, formulates and private-labels proprietary over-the-counter
topical creams, skincare products and nutritional supplements to be
marketed globally through multiple channels of distribution. In addition,
the company develops patentable compounds for entering into licensing
agreements with pharmaceutical partners. Imagenetix is the creator of
Inflame Away(TM)- Celadrin(R), which has been clinically tested to relieve
osteoarthritis pain and significantly improve joint health. For more
information, please visit imagenetix.
This document contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Such statements are
subject to risks and uncertainties that could cause actual results to vary
materially from those projected in the forward-looking statements. The
company may experience significant fluctuations in future operating results
due to a number of economic, competitive, and other factors, including,
among other things, the size and timing of customer contracts, new or
increased competition, changes in market demand, and seasonality of
purchases of the company's products and services. These factors and others
could cause operating results to vary significantly from those in prior
periods and those projected in forward-looking statements. Additional
information with respect to these and other factors, which could materially
affect the company and its operations, are included in certain forms the
company has filed and will periodically file with the Securities Exchange
Commission.
Imagenetix, Inc.
imagenetix
Комментариев нет:
Отправить комментарий